Fennec Pharmaceuticals (TSE:FRX) Sets New 1-Year Low at $7.00

Fennec Pharmaceuticals Inc. (TSE:FRX)’s stock price hit a new 52-week low during mid-day trading on Monday . The company traded as low as C$7.00 and last traded at C$7.00, with a volume of 144 shares traded. The stock had previously closed at C$7.09.

Fennec Pharmaceuticals Price Performance

The company has a 50-day moving average of C$7.95 and a 200 day moving average of C$10.20. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. The stock has a market capitalization of C$191.52 million, a PE ratio of 70.90 and a beta of 0.26.

Fennec Pharmaceuticals (TSE:FRX) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.08 by C($0.35). The business had revenue of C$9.94 million for the quarter, compared to analysts’ expectations of C$18.67 million. Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 5.59%. Sell-side analysts predict that Fennec Pharmaceuticals Inc. will post 0.6037575 EPS for the current year.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.